8-K
filed June 3, 2026, 8:31 AM ET
ticker MRVI
CIK 0001823239
debt
confidence high
sentiment positive
materiality 0.65
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI): debt financing — Maravai LifeSciences refinances credit agreement, reduces debt by ~$93M and extends maturity to 2032
MARAVAI LIFESCIENCES HOLDINGS, INC.
- New $150M term loan and $30M revolver mature June 2032; proceeds plus $98.5M cash repaid $242.9M prior debt due Oct 2027.
- Interest rate at Term SOFR + 5.00% (stepdown to 4.75% if first lien net leverage ≤ 3.0x).
- Financial covenant (max 6.5x leverage) applies only if revolver usage exceeds 40% of $30M commitment.
- Net debt reduced from $242.9M to $150.0M; revolver provides $30M additional liquidity.
- CFO Raj Asarpota cited strengthened financial foundation and preserved access to capital for growth.
Key facts
Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
MARAVAI LIFESCIENCES HOLDINGS, INC. incurred term loan of $150.0 million with BSP Agency, LLC at Term SOFR plus 5.00% per annum maturing June 2, 2032.
- Instrument
- term loan
- Principal
- $150.0 million
- Counterparty
- BSP Agency, LLC
- Rate
- Term SOFR plus 5.00% per annum
- Maturity
- June 2, 2032
- Event
- incurrence
Exact text from the filing
On June 2, 2026, Maravai Intermediate Holdings, LLC (the “Borrower”) and Maravai Topco Holdings, LLC (“Topco”), each a consolidated subsidiary controlled by Maravai LifeSciences Holdings, Inc., entered into a Credit Agreement (the “New Credit Agreement”) with certain lenders and issuing banks party thereto and BSP Agency, LLC, as administrative agent and collateral agent. The New Credit Agreement provides the Borrower with a $150.0 million term loan facility (the “New Term Loan”) and a $30.0 million revolving credit facility (the “New Revolving Credit Facility”).
View on SEC.gov
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
MARAVAI LIFESCIENCES HOLDINGS, INC. incurred revolving credit of $30.0 million with BSP Agency, LLC at Term SOFR plus 5.00% per annum maturing June 2, 2032.
- Instrument
- revolving credit
- Principal
- $30.0 million
- Counterparty
- BSP Agency, LLC
- Rate
- Term SOFR plus 5.00% per annum
- Maturity
- June 2, 2032
- Event
- incurrence
Exact text from the filing
On June 2, 2026, Maravai Intermediate Holdings, LLC (the “Borrower”) and Maravai Topco Holdings, LLC (“Topco”), each a consolidated subsidiary controlled by Maravai LifeSciences Holdings, Inc., entered into a Credit Agreement (the “New Credit Agreement”) with certain lenders and issuing banks party thereto and BSP Agency, LLC, as administrative agent and collateral agent. The New Credit Agreement provides the Borrower with a $150.0 million term loan facility (the “New Term Loan”) and a $30.0 million revolving credit facility (the “New Revolving Credit Facility”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
MARAVAI LIFESCIENCES HOLDINGS, INC. terminated Prior Credit Agreement with Morgan Stanley Senior Funding, Inc. (effective 2026-06-02).
- Action
- termination
- Agreement
- credit facility
- Counterparty
- Morgan Stanley Senior Funding, Inc.
- Effective
- 2026-06-02
Exact text from the filing
On June 2, 2026, the parties terminated the Prior Credit Agreement in connection with the Borrower’s prepayment in full of all outstanding borrowings and accrued interest thereunder.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
MARAVAI LIFESCIENCES HOLDINGS, INC. entered into New Credit Agreement with certain lenders and issuing banks valued at $150.0 million term loan facility and a $30.0 million revolving credit facility (effective 2026-06-02).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- certain lenders and issuing banks
- Value
- $150.0 million term loan facility and a $30.0 million revolving credit facility
- Effective
- 2026-06-02
Exact text from the filing
On June 2, 2026, Maravai Intermediate Holdings, LLC (the “Borrower”) and Maravai Topco Holdings, LLC (“Topco”), each a consolidated subsidiary controlled by Maravai LifeSciences Holdings, Inc., entered into a Credit Agreement (the “New Credit Agreement”) with certain lenders and issuing banks party thereto and BSP Agency, LLC, as administrative agent and collateral agent.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.